Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

PARIS, FRANCE, Feb. 28 (Korea Bizwire) – On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies and expertise built [...]